Fragment-based hit identification: thinking in 3D

Drug Discov Today. 2013 Dec;18(23-24):1221-7. doi: 10.1016/j.drudis.2013.07.011. Epub 2013 Jul 30.


The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cooperative Behavior
  • Drug Design*
  • Drug Discovery / methods*
  • Drug Industry / organization & administration
  • Drug Industry / trends
  • Humans
  • Molecular Conformation
  • Small Molecule Libraries / chemistry*


  • Small Molecule Libraries